Mirum Phase 3 EXPAND Study Meets Primary and All Five Secondary Endpoints
Mirum reported that its Phase 3 EXPAND study of LIVMARLI met the primary itch endpoint and all five secondary endpoints, with no new safety signals. The company plans to file a U.S. sNDA in H1 2027.